Reporting owner · CIK 0001613867
Behbahani Ali
Visual SEC Form 4 history across 3 companies, 20 transactions and 5 filings.
DIRCRISPR Therapeutics AG
Open-market mix
50%buys
Open-market buy performance
90-day forward return on this insider's open-market purchases
For every open-market buy (Form 4 code P, acquisition A) in the selected window, we take the closing price on the transaction date and 90 calendar days later, then compute the percentage change. The figures shown are the simple average and median of those per-buy returns.
- Window follows the rest of the summary (all-history or last 3 months).
- Only buys with a resolved price context are counted.
- Includes both positive and negative outcomes; gains and losses net out at the per-buy level.
Monthly open-market activity
Reported purchase and sale transaction counts
Buys Sells
Net value flow
Buys minus sells
Aug 25
$0
Feb 26
$15M
Sep 26
−$780.9K
Transaction texture
Ownership and ticket size
Average P/S size$7.9M
Median P/S size$7.9M
Direct6
Indirect14
Sep 18, 2026grant
Filing-only signals
Deterministic matches in this insider's history
Latest Form 4 facts
Quick context from source filings
Latest transaction
sale at CRISPR Therapeutics AG on Sep 17, 2026 valued at $780,935.
Review SEC filingAssociated companies
Visual map of known reporting history
Latest insider transactions
Form 4 filings from available history. Click any column to sort; click it again to flip the order.
| ID | Ticker | Insider | Role | Type | Shares | Value | Code | Filed | Trans date |
|---|---|---|---|---|---|---|---|---|---|
| #227121 | CRSP | Behbahani Ali | DIR | exercise | 30.0k | $0 | M | 09/21 | 09/17 |
| #227120 | CRSP | Behbahani Ali | DIR | sale | 13.6k | -$78.0M | S | 09/21 | 09/17 |
| #227119 | CRSP | Behbahani Ali | DIR | exercise | 30.0k | $42.0M | M | 09/21 | 09/17 |
| #227091 | CRSP | Behbahani Ali | DIR | other | 15 | $0 | J | 09/21 | 08/06/2025 |
| #227090 | CRSP | Behbahani Ali | DIR | other | 60 | $0 | J | 09/21 | 08/06/2025 |
| #226984 | BDTX | Behbahani Ali | DIR | grant | 7.70k | $1.48M | A | 09/21 | 09/18 |
| #65919 | SGP | Behbahani Ali | DIR | C | 402k | — | C | 02/11 | 02/09 |
| #65918 | SGP | Behbahani Ali | DIR | C | 954k | — | C | 02/11 | 02/09 |
| #65917 | SGP | Behbahani Ali | DIR | C | 737k | — | C | 02/11 | 02/09 |
| #65916 | SGP | Behbahani Ali | DIR | C | 1.37M | — | C | 02/11 | 02/09 |
Behbahani Ali Insider Activity FAQ
SEC Form 4 context
Who is Behbahani Ali?
Behbahani Ali is a reporting owner in SEC Form 4 filings with reporting owner CIK 0001613867.
Which companies has Behbahani Ali reported transactions for?
CRISPR Therapeutics AG, Black Diamond Therapeutics, Inc., SpyGlass Pharma, Inc.
When was Behbahani Ali's latest insider buy?
buy at SpyGlass Pharma, Inc. on Feb 09, 2026 valued at $15,000,000.
When was Behbahani Ali's latest insider sale?
sale at CRISPR Therapeutics AG on Sep 17, 2026 valued at $780,935.
Where can I see the original SEC filings?
Each transaction row links directly to the source SEC filing so the reported Form 4 details can be reviewed.
Are performance metrics included?
This version does not calculate win rates, forward returns, benchmark-adjusted returns, or high-conviction scores.